Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Exclusion Criteria

• •severe ulcerative colitis
• •subject in relapse for \> 6 weeks
• •use of systemic or rectal steroids within last 4 weeks prior to baseline
• •subjects with proctitis, previous colonic surgery, Crohn's disease, bleeding disorders, active ulcer disease
• •subjects hypersensitive to salicylates/aspirin
• •subjects with moderate or severe renal impairment